Conference Details - Overview

View all Conferences

Continuing Education Information

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 12.25 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.

Registered Nurses: The California Board of Registered Nursing accepts AMA PRA Category 1 Credits ™ toward license renewal. On the BRN license renewal form, report the number of hours you attended (up to 12.25 hours of credit) and fill in “CME Category 1” for the provider number.

California AB 1195: This activity complies with California Assembly Bill 1195, signed November 2005, requiring continuing medical education courses with patient care components to include curricula in the subject of cultural and linguistic competency. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area.

Seventh Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia

The Langham Huntington, Pasadena
Pasadena, CA
September 24-25, 2010

Conference Overview

Overview and Purpose
Now in its seventh year, the 2010 Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia symposium will present current standards, practical issues, and controversies in the management of myeloma, lymphoma, and leukemias. In addition, controversies in the management of these diseases will be discussed in the form of didactic lectures with panel discussions and case-based discussions with interactive audience response system capabilities. Current issues in the treatment of hematologic malignancies will be discussed in a practical context, focusing on conveying key findings from recent clinical studies that will most directly impact physician practice. Case discussions and patient management will be highlighted, providing a forum to discuss and debate the practical applicability of evolving clinical trial findings.

Target Audience
This educational program is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend.

Learning Objectives
At the conclusion of this symposium, you should be able to:

  • Implement appropriate risk stratification measures and monitoring plans for patapp:/fckEditor/editor/images/spacer.gifients with newly diagnosed myeloma, lymphoma, and leukemia
  • Discuss current treatment options for patients with newly diagnosed or relapsed/refractory myeloma, lymphoma, and leukemia
  • Assess the clinical utility of emerging novel agents for the treatment of patients with myeloma, lymphoma, and leukemia
  • Evaluate the role of hematopoietic stem cell transplantation for eligible patients with hematologic malignancies

Meeting information is accurate at the time of posting.

110-2540

Download Conference Agenda

Educational Grants

An educational grant for this activity was provided by:


  1. Millennium Pharmaceuticals, Inc.
  3. Eisai, Inc.
  4. Novartis Oncology